Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961352 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL1487007 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL765807 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL8520973 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL345859 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL11961353 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL345858 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL366852 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL16730247 | 0.84 | CA2 (0.32) | CA2 | |
| SCHEMBL3016063 | 0.84 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| EP-4263492-B1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325474-A | Spleen tyrosine kinase inhibitors | 尤尼奎斯特公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240132450-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARMACEUTICALS INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2023193054-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2023-10-12 | — | — | WO | disclosed |
| WO-2022150707-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-102796081-A | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB | 2012-11-28 | — | — | CN | disclosed |
| CN-101048401-B | Pyrimidine sulfonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB | 2012-09-12 | — | — | CN | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-7534742-B2 | Isoprenoid biosynthesis | EISENREICH WOLFGANG | 2009-05-19 | — | — | US | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
| EP-1895008-A2 | Isoprenoid biosynthesis | Bacher, Adelbert (DE) | 2008-03-05 | — | — | EP | disclosed |
| CN-101048401-A | Pyrimidine sulfonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| EP-1198575-B1 | ISOPRENOID BIOSYNTHESIS | BACHER ADELBERT (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070015216-A1 | Isoprenoid biosynthesis | EISENREICH WOLFGANG | 2007-01-18 | — | — | US | disclosed |
| US-7122331-B1 | Isoprenoid biosynthesis | EISENREICH WOLFGANG | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132450-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR65, GPR68 | L3MBTL1 3949/4885CA2 4832/4885 |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | L3MBTL1 2674/4885CA2 2634/4885 |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | L3MBTL1 818/4885CA2 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.